February 24, 2026
Gilead acquires Arcellx for its BCMA CAR-T, AnitoCell. Plus, a deep dive on validating ctDNA as a surrogate endpoint for cancer trials.
February 17, 2026
Oral SERDs show promise in breast cancer, led by Arvinus's PROTAC. Meanwhile, recent FDA setbacks for Moderna and Disc Medicine signal rising risk.
February 10, 2026
Biotech Series A funding stabilizes, compounded Wegovy threatens innovation, and neuropsych drug dev revisits past failures with new tech.
February 3, 2026
Biotech's 2026 catalysts focus on RNAi in cardiovascular and rare diseases, while China's new orphan drug law signals a major market shift.
January 27, 2026
China's new rules accelerate gene/cell therapy innovation. Plus, a look at key 2026 neuro catalysts and two newcos tackling CNS drug discovery.
January 23, 2026
Biotech's bull market is back. Experts predict a sustained recovery for 2026, fueled by new growth stories, strong M&A, and capital rotation.
January 21, 2026
This week: JPM conference takeaways, GSK's $2.2B deal, the rise of next-gen protein degraders (TACs), and the MFN drug pricing debate.
January 15, 2026
JPM conference highlights biotech's market rebound and Asia's innovation boom, focusing on China's R&D speed, Japan's VC incentives, and AI's role.
January 13, 2026
JPM kicks off with M&A rumors but no mega-deal. Experts dissect the chaotic 2026 US policy outlook and analyze 2025's FDA approval trends.
January 6, 2026
Biotech in 2026 presents a 'split screen': financial optimism and strong science are clashing with severe US policy headwinds at the FDA & NIH.
December 30, 2025
BioCentury reviews BioMarin's $4.8B Amicus deal, 2025's biotech inflection points, M&A trends, and the turbulent US regulatory forecast.
December 16, 2025
Biotech week: Hot obesity data, Chimera's degrader impresses, a record fundraising week, and a BioCentury survey reveals FDA distress.
December 9, 2025
Biotech M&A hits a decade high fueled by early-stage deals. Key clinical data emerges as major leadership turmoil at the FDA creates uncertainty.
December 2, 2025
Novo's Alzheimer's data disappoints, FDA tightens vaccine rules, and early-stage cell & gene therapy funding plummets in the US.
November 25, 2025
FDA's puzzling CRL for Sydnexus, China biotech's headwinds, CRISPR's commercial viability debated, and a look at NLRP3 inhibitors for obesity.
November 21, 2025
Voyager CEO Al Sandrock on solving CNS delivery, the future of Alzheimer's treatment, and advancing gene therapy safety for neurological diseases.
November 18, 2025
Pazdur takes over FDA's CDER, a new 'plausible mechanism' pathway emerges, SITC focuses on bispecifics, and China's RNAi space heats up.
November 13, 2025
South Korea's biotech ecosystem is a hotbed for first-in-class innovation, offering unique partnership, investment, and clinical trial advantages.
November 11, 2025
Pfizer wins Metsera after FTC scrutiny on Novo's bid. Lilly's obesity data impresses but questions muscle-sparing. FDA leadership turmoil deepens.
